Bionovo Inc.  

(Public, OTCMKTS:BNVIQ)   Watch this stock  
Jul 11 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range     -
52 week 0.00 - 0.02
Open     -
Vol / Avg. 0.00/65,381.00
Mkt cap 401,632.00
P/E     -
Div/yield     -
EPS -0.34
Shares 80.33M
Beta -2.04
Inst. own 2%

Key stats and ratios

Q1 (Mar '12) 2011
Net profit margin -15219.23% -5169.43%
Operating margin -13498.08% -8916.98%
EBITD margin - -7816.23%
Return on average assets -204.78% -87.14%
Return on average equity -417.31% -155.64%
Employees 5 -
CDP Score - -


Suite 400, 5858 Horton Street
United States - Map
+1-510-6015050 (Fax)

Website links


Bionovo, Inc. is a development-stage enterprise engaged in the development of pharmaceuticals, derived from botanical sources, to treat cancer and women�s health. Its drug candidate, Menerba (formerly MF-101), represents a class of receptor sub-type selective estrogen receptor modulator (SERM), for the treatment of vasomotor symptoms of menopause, or hot flashes. The Company has designed Menerba to modulate estrogen receptor beta (ER). In preclinical studies, Menerba does not lead to tumor formation in either breast or uterine tissues. The Company is also developing Bezielle, an oral anticancer agent for advanced breast cancer. Bezielle is designed to take advantage of a metabolism of cancer cells, with a well-characterized mechanism of action, which leads to selective tumor cell Deoxyribonucleic Acid (DNA) damage and the death of cancer cells. The Company treated 48 women with metastatic breast cancer with Bezielle in two separate Phase I clinical trials.

Officers and directors

Isaac Cohen Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
Age: 49
Mary Tagliaferri M.D. President, Chief Medical Officer, Chief Regulatory Officer, Treasurer, Secretary, Director
Age: 46
Robert E. Farrell J.D. Interim Chief Financial Officer, Independent Director
Age: 62
Louis C. Drapeau CPA Lead Independent Director
Age: 69
George C Butler Ph.D. Independent Director
Age: 64